MARKET WIRECryptonews.net • 1d ago
Hyperion DeFi Buys Back Shares and Retires Legacy DebtCryptonews.net report covering Hyperion DeFi Inc. (HYPD) market action, institutional positioning, and fundamental catalysts.
Why HYPD Stock dropped -7.76% Today — RQD Quant Desk Flash
$2.97 -7.76% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $2.92
Hyperion DeFi Inc. (HYPD) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $49.7M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on HYPD Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is HYPD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Hyperion DeFi Inc. (NASDAQ: HYPD) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $2.97 (-7.76% 1D, market cap $49.7M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, HYPD ranks #514 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does HYPD compare to IBIO and GANX in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HYPD carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 62.7%, and ROIC of -35.0%. By comparison, IBIO (iBio Inc.) holds a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $49.4M) and GANX (Gain Therapeutics Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $49.3M). Among the 5-stock peer group, HYPD leads on earnings multiple (N/A) while HYPD leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for HYPD?
▼
Per HYPD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001682639), Hyperion DeFi Inc. generated $813.5K in revenue (+1318.8% YoY), -$45.3M in net income, and -$14.8M in free cash flow against $51.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $2.92 (-1.59%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
2-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR RQD RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-9.1% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HYPD)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (38/100 Composite)
🔍 WHY HYPD SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (29% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9
▲ #2 Bullish Driver: Cash Engine Quality+9/20 pts (24% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 51% Gross Margin
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$3.47-17.6% Next Q
46
Q2 (-2Q)Grade D$2.86-0.3% Next Q
43
Q3 (-1Q)Grade D$2.85+4.2% Next Q
41
CurrentGrade D-$2.97-7.8% Hist 90D α
38
Trajectory: D (46) → D- (38)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a HYPD Turnaround Squeeze
While HYPD currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.43) and Max Pain ($3.12) forces dealer call-delta covering toward $6.80.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $HYPD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “HYPD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why HYPD Stock dropped -7.76% Today — RQD Quant Desk Flash
Hyperion DeFi Inc. (HYPD) dropped -7.76% to $2.97, trading at 15% of its 52-week range ($2.34 – $6.48). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 15% of its 52-week range ($2.34 – $6.48) with RSI-14 at 49.4 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $2.97 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 51% gross margin and $0 annual free cash flow.
Live HYPD Headlines & Catalysts
CATALYSTkalkine.ca • 1d ago
Hyperion DeFi (NASDAQ:HYPD) Penny Stock Climbs 17% Today as Buybacks and Debt Payoff Frame the Movekalkine.ca report covering Hyperion DeFi Inc. (HYPD) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 1d ago
12 Health Care Stocks Moving In Thursday's Intraday SessionBenzinga report covering Hyperion DeFi Inc. (HYPD) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESyfe • 1d ago
Marker Therapeutics, Inc. (MRKR) Stock Price & NewsSyfe report covering Hyperion DeFi Inc. (HYPD) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESyfe • 1d ago
RNAZ Stock Price, Quote & NewsSyfe report covering Hyperion DeFi Inc. (HYPD) market action, institutional positioning, and fundamental catalysts.
CATALYSTBenzinga • 5d ago
Elon Musk Notes 'Interesting' Hyperliquid Deal After Druckenmiller EndorsementElon Musk calls Hyperliquid’s ICE deal “interesting,” extending HYPE’s rally to 17% after Stan Druckenmiller’s public backing.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring HYPD)
- ✓Walkthrough of HYPD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
HYPD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -34.00%📐 HORIZONTAL RANGE
2026-11-03O $3.50H $3.50L $2.97C $2.97VOL 356.4K
RES: $4.24SUP: $2.66SMA50: $3.43SMA200: $3.36
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
HYPD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +1318.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on HYPD today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for HYPD. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for HYPD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HYPD)
Health Care Rank #514 of 1015
⚔️ IBIO vs HYPD Full Matrix →
1. Head-to-Head Health Care Peer Comparison (HYPD vs. IBIO, GANX, SER, CNTB)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Hyperion DeFi Inc. (HYPD) ranks #514 by composite RQD confidence (38/100, grade D-) and #744 by equity capitalization ($49.7M). Within this direct 5-issuer industry benchmark cohort, HYPD leads on earnings valuation at N/A trailing P/E, while HYPD leads on capital efficiency and profitability with -35.0% ROIC and 62.7% gross margin. GANX currently holds the highest overall quantitative score in the immediate peer group at 41/100 (D-) compared with HYPD at 38/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| HYPD
ACTIVE
Hyperion DeFi Inc. | D- | 38/100 | — | 62.7% | -35.0% | -7.76% | $49.7M | Benchmark Subject |
| IBIO iBio Inc. | E | 23/100 | — | — | -35.0% | +4.06% | $49.4M | /ibio-vs-hypd → |
| GANX Gain Therapeutics Inc. | D- | 41/100 | — | — | -35.0% | 0.00% | $49.3M | /ganx-vs-hypd → |
| SER Serina Therapeutics Inc. | E | 31/100 | — | — | -35.0% | -4.64% | $49.3M | /ser-vs-hypd → |
| CNTB Connect Biopharma Holdings Limited | E | 26/100 | — | — | -35.0% | -3.13% | $50.5M | /cntb-vs-hypd → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001682639 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Hyperion DeFi Inc. (HYPD) reported GAAP revenue of $813.5K (+1318.8% vs. FY2024 revenue of $57.3K , and +21380.2% cumulative change since FY2023) , GAAP net income of -$45.3M, operating cash flow of -$14.8M, and free cash flow of -$14.8M (+51.2% YoY). On the balance sheet, HYPD closed FY2025 with $51.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $813.5K | -$45.3M | -$14.8M | -$14.8M | $51.8M | — |
| FY2024 (FY) | 2024-12-31 | $57.3K | -$49.8M | -$30.1M | -$30.3M | $3.7M | — |
| FY2023 (FY) | 2023-12-31 | $3.8K | -$27.3M | -$23.8M | -$23.8M | — | — |
3. HYPD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs HYPD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Hyperion DeFi Inc. (NASDAQ: HYPD) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $2.97 (-7.76% 1D, market cap $49.7M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, HYPD ranks #514 in composite RQD confidence.
How does HYPD compare to IBIO and GANX in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HYPD carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 62.7%, and ROIC of -35.0%. By comparison, IBIO (iBio Inc.) holds a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $49.4M) and GANX (Gain Therapeutics Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $49.3M). Among the 5-stock peer group, HYPD leads on earnings multiple (N/A) while HYPD leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for HYPD?
Per HYPD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001682639), Hyperion DeFi Inc. generated $813.5K in revenue (+1318.8% YoY), -$45.3M in net income, and -$14.8M in free cash flow against $51.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is HYPD trading relative to its 50-day, 200-day, and 52-week technical levels?
HYPD last traded at $2.97 (-7.76% on volume of 158,922 shares), positioning the stock -13.41% below its 50-day simple moving average ($3.43) and -11.61% below its 200-day simple moving average ($3.36). Across its 52-week range of $2.34 to $6.48, HYPD sits at the 15.2% percentile with a 14-day RSI of 49.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.60 to $3.34).
ROARABLE RATING BRIEF • RQD 38/100 (D-)
✓ SEC XBRL & RQD VERIFIED
HYPD — Hyperion DeFi Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Hyperion DeFi Inc. (HYPD) earns a live Roarable RQD composite score of 38/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $2.97 (-7.76% 1D, market capitalization $49.7M).
- Fundamental Cash Engine (9/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 62.7%, operating margin of -60.0%, and free cash flow yield of —.
- Whale 13F & Options Flow (6/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (7/20) + Forensic Balance Sheet (11/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 5/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Hyperion DeFi Inc. Is listed on NASDAQ under the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry. The profile describes the issuer as operating in this industry with a market capitalization of $0.1B.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Hyperion DeFi Inc. (HYPD) reported $813.5K in annual revenue (up from $57.3K in FY2024, +1318.8% YoY) and -$45.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($3.8K revenue, -$27.3M net income) through FY2025, HYPD scaled operating cash flow to -$14.8M and free cash flow to -$14.8M, backed by $51.8M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D- • RQD 38/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 6/20. With Fundamental Cash Engine at 9/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $2.34 – $6.48 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Operating in Biotechnology: Pharmaceutical Preparations (Health Care), HYPD carries a macro regime beta of 1.00 and gross margin of 62.7%.
- Key Question #1: Can HYPD sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $813.5K and free cash flow of -$14.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is HYPD's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
HYPD Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Hyperion DeFi Inc. (HYPD) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Cryptonews.net • 1d ago
Hyperion DeFi Buys Back Shares and Retires Legacy Debt Cryptonews.net report covering Hyperion DeFi Inc. (HYPD) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST kalkine.ca • 1d ago
Hyperion DeFi (NASDAQ:HYPD) Penny Stock Climbs 17% Today as Buybacks and Debt Payoff Frame the Move kalkine.ca report covering Hyperion DeFi Inc. (HYPD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 1d ago
12 Health Care Stocks Moving In Thursday's Intraday Session Benzinga report covering Hyperion DeFi Inc. (HYPD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Syfe • 1d ago
Marker Therapeutics, Inc. (MRKR) Stock Price & News Syfe report covering Hyperion DeFi Inc. (HYPD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Syfe • 1d ago
RNAZ Stock Price, Quote & News Syfe report covering Hyperion DeFi Inc. (HYPD) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Benzinga • 5d ago
Elon Musk Notes 'Interesting' Hyperliquid Deal After Druckenmiller Endorsement Elon Musk calls Hyperliquid’s ICE deal “interesting,” extending HYPE’s rally to 17% after Stan Druckenmiller’s public backing.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
HYPD Bull vs. Bear Conversation Board — What's Your Call at $2.97?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON HYPD 🐻 33% BEARISH CONVICTION
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH
🎯 Target: $4.09 (+27.0%)
📌 Pinned Debate Reported cash rose from $2.1M in FY 2024 to $6.3M in FY 2025 while buybacks and debt retirement are cited in news coverage.
Reported cash rose from $2.1M in FY 2024 to $6.3M in FY 2025 while buybacks and debt retirement are cited in news coverage.. When you look under the hood at HYPD, Fundamental Cash Engine is 9/20 with 62.7% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (6/20) has been quietly accumulating below $6.87. My 12M target is $4.09.
VolSurface_Trader 🐂 BULL
@MultipleCompression Shorting a 6/20 institutional whale-flow stock at $3.22 is dangerous when funds are rotating into Health Care.
MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH
🎯 Target: $2.58 (-19.9%)
Spot @ $3.22 Operating margin of -60% and ROIC of -35% alongside a 0% FCF yield show the business is not currently generating returns on capital.
Fading this rally in HYPD at $3.22. Operating margin of -60% and ROIC of -35% alongside a 0% FCF yield show the business is not currently generating returns on capital.. With a beta of 1.0 and the stock sitting at $3.22 (52-wk range $2.34–$6.87), the easy multiple expansion is already priced in.